Vertex Pharmaceuticals
VRTX
1,223 hedge funds and large institutions have $68.1B invested in Vertex Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 185 funds opening new positions, 439 increasing their positions, 438 reducing their positions, and 64 closing their positions.
189% more first-time investments, than exits
New positions opened: 185 | Existing positions closed: 64
9% more funds holding
Funds holding: 1,127 → 1,223 (+96)
8% more call options, than puts
Call options by funds: $420M | Put options by funds: $390M
0% more repeat investments, than reductions
Existing positions increased: 439 | Existing positions reduced: 438
0.43% less ownership
Funds ownership: 92.49% → 92.06% (-0.43%)
1% less capital invested
Capital invested by funds: $68.5B → $68.1B (-$431M)
31% less funds holding in top 10
Funds holding in top 10: 39 → 27 (-12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$195M |
| 2 |
JP Morgan Chase
New York
|
+$192M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$152M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$132M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$126M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$404M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$366M |
| 3 |
BlackRock
New York
|
-$305M |
| 4 |
Lazard Asset Management
New York
|
-$147M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$141M |
VRTX Hedge Fund Activity: Q4 2022 in Review
1,223 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2022, worth a combined $68.1B — down 0.63% from $68.5B a quarter earlier.
Buyers outnumbered sellers: 185 funds opened new VRTX positions and 64 closed out — a net gain of 121 holders — while 439 added to existing stakes and 438 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $195M. The largest seller was Canada Pension Plan Investment Board, cutting an estimated $404M.
- 1,223 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2022, up from 1,127 in Q3 2022.
- Funds reported $68.1B of Vertex Pharmaceuticals stock for Q4 2022, down 0.63% quarter-over-quarter.
- 185 funds opened new Vertex Pharmaceuticals positions in Q4 2022 and 64 closed out, a net change of +121 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2022 was Morgan Stanley, an estimated $195M added.
- The largest Vertex Pharmaceuticals seller in Q4 2022 was Canada Pension Plan Investment Board, an estimated $404M sold.
Based on aggregated 13F filings for Q4 2022.